Clinical Trial Detail

NCT ID NCT02747537
Title Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Washington University School of Medicine

Advanced Solid Tumor


Irinotecan + Sorafenib

Age Groups: child adult

Additional content available in CKB BOOST